<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02111798</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00090062</org_study_id>
    <secondary_id>DA034-047</secondary_id>
    <secondary_id>R01DA034047</secondary_id>
    <nct_id>NCT02111798</nct_id>
  </id_info>
  <brief_title>Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence</brief_title>
  <official_title>Bupropion-Enhanced CM for Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will examine effects of bupropion extended release (XL) at a dose of 300mg/day&#xD;
      for cocaine abstinence among persons receiving methadone for the treatment of opioid use&#xD;
      disorder. Participants also earned financial incentives for providing urine samples that&#xD;
      tested negative for cocaine. Bupropion was examined for this purpose because of its&#xD;
      previously demonstrated efficacy and safety as well as its pharmacological actions at&#xD;
      dopamine systems. Participants were randomly assigned to bupropion XL vs. placebo and&#xD;
      received different incentive schedules depending on whether they demonstrated abstinence from&#xD;
      cocaine early in the study. Outcomes were tracked over a 6-month time frame and the&#xD;
      overarching hypothesis was that bupropion (as compared to placebo) would increase the number&#xD;
      of urine samples testing negative for cocaine, independent of whether participants&#xD;
      demonstrated abstinence from cocaine early in the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The efficacy of behavior therapies may be enhanced by certain medications, particularly those&#xD;
      that act on dopaminergic systems. The purpose of this project is to examine effects of&#xD;
      bupropion on initiation and maintenance of cocaine abstinence in a population of persons&#xD;
      being treated with methadone for the treatment of opioid use disorder who are concurrently&#xD;
      using cocaine. Bupropion appears to be the most promising medication for this purpose because&#xD;
      of its previously demonstrated efficacy and safety as well as its pharmacological actions at&#xD;
      dopamine systems.&#xD;
&#xD;
      Participants will be eligible for inclusion in the study if they are 1) enrolled in methadone&#xD;
      maintenance treatment, having previously met the criteria for opioid dependence; 2) between&#xD;
      the ages of 18 and 65; 3) provide evidence of cocaine dependence (DSM-IV criteria,&#xD;
      self-report, and/or urine tests positive for cocaine during the intake process); and 4) are&#xD;
      willing to take study medications and adhere to reporting and data collection schedules.&#xD;
&#xD;
      They will be excluded if they have 1) a history of epilepsy or seizure, including alcohol- or&#xD;
      cocaine-related seizure; 2) conditions with increased risk of seizure (e.g. head trauma with&#xD;
      loss of consciousness &gt; 30 mins), 3) current use (past 30 days) of antidepressants,&#xD;
      antipsychotics, theophyllines, systemic steroids, MAO-A inhibitors, 4) recent use (past 30&#xD;
      days of any medication containing bupropion or budeprion (Wellbutrin®, Zyban®), 5) allergy to&#xD;
      bupropion or budeprion, 6) liver enzyme levels greater than 3x upper limit of normal (ULN);&#xD;
      7) uncontrolled diabetes mellitus (glucose &gt; 200mg%); 8) severe psychiatric diagnosis:&#xD;
      schizophrenia, psychosis, major depression, mania, current suicidal ideation with plan;&#xD;
      cognitive impairment severe enough to preclude informed consent or valid responses on&#xD;
      questionnaires; 9) severe renal insufficiency (eGFR &lt; 30 ml/min), 10) pregnant, breast&#xD;
      feeding or unwilling to use birth control, 11) medical illness that in the view of the&#xD;
      investigators would compromise participation in research, 12) advanced HIV infection&#xD;
      requiring HAART 13) current eating disorder (anorexia or bulimia), 14) uncontrolled&#xD;
      hypertension with blood pressure ( BP) &gt;140/90.&#xD;
&#xD;
      All participants will be randomly assigned to receive bupropion XL (300mg/day) or placebo. In&#xD;
      addition, study participants will also receive an add-on incentive-based intervention&#xD;
      depending upon whether they provide 6 consecutive-urine samples that test negative for&#xD;
      cocaine. Those who provide 6 consecutive negative urine samples will earn incentives for&#xD;
      continuing to provide negative sample (Relapse Prevention group) and those who do not achieve&#xD;
      this threshold will earn a different schedule of incentives to promote abstinence (Abstinence&#xD;
      Initiation). Our hypothesis is that bupropion as compared to placebo treatment will both&#xD;
      enhance the number of urine samples testing negative for cocaine. All participants will be&#xD;
      eligible to earn $675 in incentives and cocaine use will be monitored via thrice weekly urine&#xD;
      samples collected for a 6 month period.&#xD;
&#xD;
      Overall, this research will provide new and valuable information about the use of bupropion&#xD;
      XL to enhance provision of cocaine-negative urine samples in persons independent of their&#xD;
      early abstinence behaviors. If hypothesized synergies can be demonstrated, the study will&#xD;
      point the way to a significant advance in improved treatment outcomes for this critical group&#xD;
      of drug abusers. The proposed study is compelling because it conceptually differentiates the&#xD;
      two key clinical issues in treatment of stimulant abusers- abstinence initiation and relapse&#xD;
      prevention. It uses a design that efficiently and effectively tests a combined treatment&#xD;
      approach for each clinical issue and as well examines cognitive function and&#xD;
      reinforcement-based mediators. The research will add to understanding of the interplay&#xD;
      between brain reinforcement systems and drug-seeking behavior. Finally, it will make an&#xD;
      important contribution to behavioral therapy development by exploring a novel solution to&#xD;
      limitations previously noted for CM that include lack of response in some patients and&#xD;
      relapse after withdrawal of incentives.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">January 2021</completion_date>
  <primary_completion_date type="Actual">May 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Cocaine Negative Urines</measure>
    <time_frame>Weeks 7-30</time_frame>
    <description>Comparison of the number of thrice-weekly urine tests submitted during weeks study 7-30 negative for cocaine for persons randomly assigned to receive placebo or bupropion XL during weeks 7-30; excused samples are omitted and missing samples are treated as positive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Longest Consecutive Period of Negative Urine Samples</measure>
    <time_frame>Weeks 7-30</time_frame>
    <description>Comparison of the longest string of urine samples testing negative for cocaine that were submitted at thrice weekly visits between weeks 7-30 from persons who were randomly assigned to receive placebo or bupropion XL; samples that were excused are omitted otherwise missing samples are treated as positive.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Substance Abuse</condition>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Placebo/Abstinence Initiation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In week 2 participants will randomly assigned to receive twice daily capsules filled with placebo powder. At the end of week 6, participants who did not provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupropion XL/Abstinence Initiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In week 2 participants will randomly assigned to receive bupropion 150mg capsules filled with placebo powder. At the end of week 6, participants who did not provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/Relapse Prevention</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In week 2 participants will randomly assigned to receive twice daily capsules filled with placebo powder. At the end of week 6, participants who did provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupropion XL/Relapse Prevention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In week 2 participants will randomly assigned to receive bupropion 150mg capsules filled with placebo powder. At the end of week 6, participants who did provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial will be assigned to the Abstinence Initiation incentive arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will be randomly assigned to receive placebo powder in twice-daily capsules at the end of week 2.</description>
    <arm_group_label>Placebo/Abstinence Initiation</arm_group_label>
    <arm_group_label>Placebo/Relapse Prevention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion XL</intervention_name>
    <description>Participants will be randomly assigned to receive bupropion XL 150mg/day in twice-daily capsules at the end of week 2.</description>
    <arm_group_label>Bupropion XL/Abstinence Initiation</arm_group_label>
    <arm_group_label>Bupropion XL/Relapse Prevention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Abstinence Initiation</intervention_name>
    <description>Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who do not provide 3 urine samples that test negative for cocaine by the end of week 6 will be assigned to an Abstinence Incentive condition.</description>
    <arm_group_label>Bupropion XL/Abstinence Initiation</arm_group_label>
    <arm_group_label>Placebo/Abstinence Initiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Relapse Prevention</intervention_name>
    <description>Participants will provide urine samples thrice weekly during weeks 1-6 of the study. Urine samples will be tested immediately onsite for evidence of recent cocaine exposure. Participants who provide 3 urine samples that test negative for cocaine will be promptly assigned to a Relapse Prevention incentive condition.</description>
    <arm_group_label>Bupropion XL/Relapse Prevention</arm_group_label>
    <arm_group_label>Placebo/Relapse Prevention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Enrolled in methadone maintenance&#xD;
&#xD;
          -  Meets Diagnostic and Statistical Manual of Mental Disorders, Fifth edition (DSM V)&#xD;
             criteria for active cocaine use&#xD;
&#xD;
          -  Submits one cocaine positive urine sample within 30 days of study start&#xD;
&#xD;
          -  Agrees to study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Healthy and without contra-indications to study medication&#xD;
&#xD;
          -  Any history of epilepsy or seizure, including alcohol-, sedative-, or cocaine-related&#xD;
             seizure&#xD;
&#xD;
          -  Any increased risk of seizure such as serious head trauma with a loss of consciousness&#xD;
             of more than an hour duration, brain tumor, or other brain pathology increasing risk&#xD;
             of seizure.&#xD;
&#xD;
          -  Current eating disorder including anorexia or bulimia&#xD;
&#xD;
          -  Current use (last 30 days) of antidepressants, antipsychotics, theophyllines, systemic&#xD;
             steroids, monoamine oxidase (MAO-A) inhibitors.&#xD;
&#xD;
          -  Recent use (last 30 days) of budeprion, zyban®, wellbutrin®, aplenzin®, or any other&#xD;
             medication containing bupropion.&#xD;
&#xD;
          -  Allergy to bupropion or budeprion&#xD;
&#xD;
          -  Liver enzymes greater than 3x ULN (upper limit of normal)&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus, or h/o diabetic coma&#xD;
&#xD;
          -  Uncontrolled hypertension with BP &gt; 140/90.&#xD;
&#xD;
          -  Current psychiatric diagnosis: schizophrenia, psychosis, major depression, mania,&#xD;
             current suicidal ideation as determined by MINI psychiatric interview, cognitive&#xD;
             impairment severe enough to preclude informed consent or valid responses on&#xD;
             questionnaires&#xD;
&#xD;
          -  Severe renal insufficiency (eGFR &lt; 30 ml/min)&#xD;
&#xD;
          -  Pregnancy or current breast feeding,&#xD;
&#xD;
          -  Medical illness that in the view of the investigators would compromise participation&#xD;
             in research, such as uncompensated congestive heart failure, recent history of&#xD;
             myocardial infarction (&lt;1year), or urologic conditions that inhibit urine collection.&#xD;
&#xD;
          -  Advanced HIV infection requiring the use of HAART (Highly Active Anti-Retroviral&#xD;
             Therapy), or with CD4 T cell count &lt; 200/uL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelly Dunn, Ph.D., MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Behavioral Pharmacology Research Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Behavioral Resources</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 28, 2014</study_first_submitted>
  <study_first_submitted_qc>April 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2014</study_first_posted>
  <results_first_submitted>May 17, 2021</results_first_submitted>
  <results_first_submitted_qc>August 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 20, 2021</results_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>substance abuse treatment</keyword>
  <keyword>cocaine dependence</keyword>
  <keyword>contingency management; abstinence incentives</keyword>
  <keyword>medication-enhanced behavioral therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT02111798/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/98/NCT02111798/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo/Abstinence Initiation</title>
          <description>Twice daily capsules filled with placebo powder + participants who did not provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial</description>
        </group>
        <group group_id="P2">
          <title>Bupropion XL/Abstinence Initiation</title>
          <description>Twice daily capsules filled with bupropion extended release, 150mg (300mg daily) + participants who did not provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial</description>
        </group>
        <group group_id="P3">
          <title>Placebo/Relapse Prevention</title>
          <description>Twice daily capsules filled with placebo + participants who provided &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial</description>
        </group>
        <group group_id="P4">
          <title>Bupropion XL/Relapse Prevention</title>
          <description>Twice daily capsules filled with bupropion extended release, 150mg (300mg daily) + participants who did provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo/Abstinence Initiation</title>
          <description>Twice daily capsules filled with placebo powder + participants who did not provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial</description>
        </group>
        <group group_id="B2">
          <title>Bupropion XL/Abstinence Initiation</title>
          <description>Twice daily capsules filled with bupropion 150mg + participants who did not provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial</description>
        </group>
        <group group_id="B3">
          <title>Placebo/Relapse Prevention</title>
          <description>Twice daily capsules filled with placebo powder + participants who did provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial</description>
        </group>
        <group group_id="B4">
          <title>Bupropion XL/Relapse Prevention</title>
          <description>Twice daily capsules filled with bupropion 150mg + participants who did provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="83"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.4" spread="4.9"/>
                    <measurement group_id="B2" value="46.5" spread="9.3"/>
                    <measurement group_id="B3" value="48.5" spread="9.8"/>
                    <measurement group_id="B4" value="41.3" spread="11.8"/>
                    <measurement group_id="B5" value="45.2" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Cocaine Negative Urines</title>
        <description>Comparison of the number of thrice-weekly urine tests submitted during weeks study 7-30 negative for cocaine for persons randomly assigned to receive placebo or bupropion XL during weeks 7-30; excused samples are omitted and missing samples are treated as positive.</description>
        <time_frame>Weeks 7-30</time_frame>
        <population>Comparisons are conducted as a function of study medication as that is the only variable for which randomization occurred.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Abstinence Initiation</title>
            <description>Twice daily capsules filled with placebo powder + participants who did not provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial</description>
          </group>
          <group group_id="O2">
            <title>Bupropion XL/Abstinence Initiation</title>
            <description>Twice daily capsules filled with bupropion XL 150mg + participants who did not provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Relapse Prevention</title>
            <description>Twice daily capsules filled with placebo powder + participants who did provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial</description>
          </group>
          <group group_id="O4">
            <title>Bupropion XL/Relapse Prevention</title>
            <description>Twice daily capsules filled with bupropion XL 150mg + participants who not provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cocaine Negative Urines</title>
          <description>Comparison of the number of thrice-weekly urine tests submitted during weeks study 7-30 negative for cocaine for persons randomly assigned to receive placebo or bupropion XL during weeks 7-30; excused samples are omitted and missing samples are treated as positive.</description>
          <population>Comparisons are conducted as a function of study medication as that is the only variable for which randomization occurred.</population>
          <units>Mean percent negative urines</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.6" spread=".01"/>
                    <measurement group_id="O2" value="57.7" spread=".01"/>
                    <measurement group_id="O3" value="4.2" spread=".01"/>
                    <measurement group_id="O4" value="14.5" spread=".01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparisons were conducted as a function of medication condition, collapsed across abstinence initiation and relapse prevention groups, according to a priori-stated statistical analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.889</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Longest Consecutive Period of Negative Urine Samples</title>
        <description>Comparison of the longest string of urine samples testing negative for cocaine that were submitted at thrice weekly visits between weeks 7-30 from persons who were randomly assigned to receive placebo or bupropion XL; samples that were excused are omitted otherwise missing samples are treated as positive.</description>
        <time_frame>Weeks 7-30</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/Abstinence Initiation</title>
            <description>Twice daily capsules filled with placebo powder + participants who did not provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial</description>
          </group>
          <group group_id="O2">
            <title>Bupropion XL/Abstinence Initiation</title>
            <description>Twice daily capsules filled with bupropion XL 150mg + participants who did not provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial</description>
          </group>
          <group group_id="O3">
            <title>Placebo/Relapse Prevention</title>
            <description>Twice daily capsules filled with placebo powder + participants who did provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial</description>
          </group>
          <group group_id="O4">
            <title>Bupropion XL/Relapse Prevention</title>
            <description>Twice daily capsules filled with bupropion Xl 150mg + participants who did provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial</description>
          </group>
        </group_list>
        <measure>
          <title>Longest Consecutive Period of Negative Urine Samples</title>
          <description>Comparison of the longest string of urine samples testing negative for cocaine that were submitted at thrice weekly visits between weeks 7-30 from persons who were randomly assigned to receive placebo or bupropion XL; samples that were excused are omitted otherwise missing samples are treated as positive.</description>
          <units>Mean consecutive negative urines</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="2.0"/>
                    <measurement group_id="O2" value="11.25" spread="3.3"/>
                    <measurement group_id="O3" value="52.9" spread="7.0"/>
                    <measurement group_id="O4" value="33.3" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparisons were conducted as a function of medication condition, collapsed across abstinence initiation and relapse prevention groups, according to a priori-stated statistical analysis.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.605</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events represent all events rated as &quot;possibly, probably, or definitely&quot; related to study participation, that were reported by participants to study staff during thrice weekly visits over a 23 week period during study weeks 7 - 30.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo/Abstinence Initiation</title>
          <description>Twice daily capsules filled with placebo powder + participants who did not provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial</description>
        </group>
        <group group_id="E2">
          <title>Bupropion XL/Abstinence Initiation</title>
          <description>Twice daily capsules filled with bupropion XL 150mg + participants who did not provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial</description>
        </group>
        <group group_id="E3">
          <title>Placebo/Relapse Prevention</title>
          <description>Twice daily capsules filled with placebo powder + participants who did provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial</description>
        </group>
        <group group_id="E4">
          <title>Bupropion XL/Relapse Prevention</title>
          <description>Twice daily capsules filled with bupropion XL 150mg + participants who did provide &gt;/=3 consecutive negative urine samples during weeks 1-6 of the trial</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach cramps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal Cramps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Gastro Esophageal Reflux Disease (GERD)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain, Lower Extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kelly Dunn, Ph.D., MBA</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>410-550-2254</phone>
      <email>kdunn9@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

